Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents

被引:40
作者
Suzuki, N [1 ]
Del Villar, K [1 ]
Tamanoi, F [1 ]
机构
[1] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA
关键词
D O I
10.1073/pnas.95.18.10499
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Farnesyltransferase inhibitors (FTIs) exhibit the remarkable ability to inhibit transformed phenotypes of a variety of human cancer cell lines and to block the growth of cancer cells in a number of animal model systems. In this paper, we report that the addition of FTI to v-K-ras-transformed NRK cells (KNRK) results in dramatic morphological changes. Within 24 h after the addition of FTI, the round morphology of KNRK cells was changed to an elongated (flattened and spread out) morphology resembling those of untransformed NRK cells. No morphological effects were seen when similar concentrations of FTI were added to NRK cells. Phalloidin staining showed that FTI treatment did not restore the disrupted actin cytoskeleton in KNRK cells. In contrast, FTI addition resulted in the appearance of extensive microtubule networks in KNRK cells. The addition of a low concentration (1.2 nM) of vincristine or vinblastine, agents that interfere with microtubule dynamics, blocked the FTI-induced morphological changes in KNRK cells, In contrast, cytochalasin B, which interferes with actin polymerization, did not block the morphological changes. The FTI-induced morphological changes were associated with a decrease in the percentage of cells in S-phase, and the addition of 1.2 nM vincristine did not have additional effects on cell cycle progression. A higher concentration (12 nM) of vincristine caused synergistic effect with FTI to enrich dramatically KNRK cells in G(2)/M phase. These results suggest that FTI affects cell morphology and that microtubule dynamics are involved in these processes.
引用
收藏
页码:10499 / 10504
页数:6
相关论文
共 40 条
[1]   CHARACTERIZATION OF MURINE SARCOMA VIRUS (KIRSTEN) TRANSFORMATION OF MOUSE AND HUMAN CELLS [J].
AARONSON, SA ;
WEAVER, CA .
JOURNAL OF GENERAL VIROLOGY, 1971, 13 (NOV) :245-&
[2]   From bench top to bedside [J].
Barinaga, M .
SCIENCE, 1997, 278 (5340) :1036-1039
[3]   A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis [J].
Barrington, RE ;
Subler, MA ;
Rands, E ;
Omer, CA ;
Miller, PJ ;
Hundley, JE ;
Koester, SK ;
Troyer, DA ;
Bearss, DJ ;
Conner, MW ;
Gibbs, JB ;
Hamilton, K ;
Koblan, KS ;
Mosser, SD ;
O'Neill, TJ ;
Schaber, MD ;
Senderak, ET ;
Windle, JJ ;
Oliff, A ;
Kohl, NE .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (01) :85-92
[4]   Novel tricyclic inhibitors of farnesyl protein transferase - Biochemical characterization and inhibition of Ras modification in transfected Cos cells [J].
Bishop, WR ;
Bond, R ;
Petrin, J ;
Wang, L ;
Patton, R ;
Doll, R ;
Njoroge, G ;
Catino, J ;
Schwartz, J ;
Windsor, W ;
Syto, R ;
Schwartz, J ;
Carr, D ;
James, L ;
Kirschmeier, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (51) :30611-30618
[5]   ISOPRENOID MODIFICATION PERMITS 2',3'-CYCLIC NUCLEOTIDE 3'-PHOSPHODIESTERASE TO BIND TO MEMBRANES [J].
BRAUN, PE ;
DEANGELIS, D ;
SHTYBEL, WW ;
BERNIER, L .
JOURNAL OF NEUROSCIENCE RESEARCH, 1991, 30 (03) :540-544
[6]  
Clark GJ, 1997, J BIOL CHEM, V272, P10608
[7]   ACTIVATION OF MAP KINASE KINASE IS NECESSARY AND SUFFICIENT FOR PC12 DIFFERENTIATION AND FOR TRANSFORMATION OF NIH 3T3 CELLS [J].
COWLEY, S ;
PATERSON, H ;
KEMP, P ;
MARSHALL, CJ .
CELL, 1994, 77 (06) :841-852
[8]   Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? [J].
Cox, AD ;
Der, CJ .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1997, 1333 (01) :F51-F71
[9]   ISOPRENYLATION OF BRAIN 2',3'-CYCLIC NUCLEOTIDE 3'-PHOSPHODIESTERASE MODULATES CELL MORPHOLOGY [J].
DEANGELIS, DA ;
BRAUN, PE .
JOURNAL OF NEUROSCIENCE RESEARCH, 1994, 39 (04) :386-397
[10]  
DeAngelis DA, 1996, J NEUROCHEM, V66, P2523